Does the severity of the LGMD2A phenotype in compound heterozygotes depend on the combination of mutations?

Amets Sáenz(Instituto de Salud Carlos III), Adolfo López de Munaín(Universidad de Deusto), Lorea Blázquez, Juan José Poza(Biomedical Research Networking Center on Neurodegenerative Diseases), Miguel Urtasun(Instituto de Salud Carlos III), Hiroyuki Sorimachi(Japan Science and Technology Agency), Alberto Marina(Centro de Investigación Biomédica en Red), María Goicoechea(Instituto de Salud Carlos III), France Leturcq(Centre National de la Recherche Scientifique), F. García-Bragado(Hospital Virgen del Camino), Naoko Doi(Tokushima Municipal Hospital), Margarita Azpitarte(Biogipuzkoa Health Research Institute), Jean‐Claude Kaplan(Centre National de la Recherche Scientifique), Yasuko Ono(Tokyo Metropolitan Institute of Medical Science)
Muscle & Nerve
June 6, 2011
Cited by 13


Related Papers